Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic biology company that became publicly traded in September 2021 through a SPAC merger with Soaring Eagle Acquisition Corp., a blank-check vehicle sponsored by Eagle Equity Partners, the partnership of producers Harry Sloan and Jeff Sagansky alongside Eli Baker. The company, which operates a cell-programming platform serving pharmaceutical, agriculture, and industrial biotechnology customers, filed its annual Form 10-K with the SEC on February 26, 2026, covering fiscal year 2025. Ginkgo has remained a closely watched post-merger name in the life sciences sector since its de-SPAC transaction. For full filing details, financial metrics, and ongoing SPAC deal tracking, create a free account at SpacDesk.